An Overview of Antiviral Treatments in Pregnancy
Copyright © 2022 Elsevier Inc. All rights reserved..
Viral infections pose unique threats to pregnant persons and their infants. As the frequency of epidemics caused by novel pathogens increases, understanding pregnancy-specific considerations for antiviral treatments is critical for obstetric and nonobstetric providers alike. The use of pharmacologic therapeutics in pregnancy, which include antivirals, pathogen-specific antibodies, and vaccines, is limited due to the lack of purposeful, methodologic, pharmacometrics analyses in this special population. Our current understanding regarding dosing, safety, and efficacy stems from our knowledge of potential maternal or neonatal risks, observational data, and rarely clinical trials. In this review, we provide an overview on the use of antivirals during pregnancy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology clinics of North America - 50(2023), 1 vom: 01. März, Seite 183-203 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Joseph, Naima T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 27.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ogc.2022.10.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353289418 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353289418 | ||
| 003 | DE-627 | ||
| 005 | 20231226055643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ogc.2022.10.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353289418 | ||
| 035 | |a (NLM)36822703 | ||
| 035 | |a (PII)S0889-8545(22)00108-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Joseph, Naima T |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Overview of Antiviral Treatments in Pregnancy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Viral infections pose unique threats to pregnant persons and their infants. As the frequency of epidemics caused by novel pathogens increases, understanding pregnancy-specific considerations for antiviral treatments is critical for obstetric and nonobstetric providers alike. The use of pharmacologic therapeutics in pregnancy, which include antivirals, pathogen-specific antibodies, and vaccines, is limited due to the lack of purposeful, methodologic, pharmacometrics analyses in this special population. Our current understanding regarding dosing, safety, and efficacy stems from our knowledge of potential maternal or neonatal risks, observational data, and rarely clinical trials. In this review, we provide an overview on the use of antivirals during pregnancy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antivirals | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Viral infections | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Banga, Jaspreet |e verfasserin |4 aut | |
| 700 | 1 | |a Badell, Martina L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology clinics of North America |d 1995 |g 50(2023), 1 vom: 01. März, Seite 183-203 |w (DE-627)NLM012977047 |x 1558-0474 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:1 |g day:01 |g month:03 |g pages:183-203 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ogc.2022.10.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 1 |b 01 |c 03 |h 183-203 | ||